Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.3052W HIGH $31.70
Volume
4.25 M
Value Traded
120.79 M
Short % Float
11.9%
+539.54%5 Year
+539.54%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
445.55 M
EPS (TTM)
0.00
P/E Ratio
5990.82
Ent. Value
445.28 M
Total Shares
17.18 M
Float Shares
4.83 M
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
MCTA Catalyst Timeline
Dated clinical, regulatory and corporate events for Charming Medical Limited
Past FDA Catalysts and PDUFA Decisions
How MCTA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every MCTA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in MCTA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MCTA for Q2 2026. | ||||
Ownership Trends
MCTA Short Interest
Shares sold short, counted twice a month.
11.9%
Short % of Float
of tradable shares sold short
574.5K
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
0
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MCTA ranks across every disease it competes in
Competitive Position is a premium feature
See how MCTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMCTA News
-MCTA
Nov 5, 2026▲ +3.5%today
Charming Medical Limited Announces Receipt of Nasdaq Delisting Determination Notice.
Charming Medical Limited announced it received a delisting notice from Nasdaq due to potential manipulation of its securities. The SEC had previously suspended trading of the company's shares. Unless an appeal is filed by November 5, 2026, trading will cease on November 9, 2026. The company maintains that its business operations remain unaffected.
Read more →-MCTA
Mar 31, 2026CHARMING MEDICAL LIMITED AND ITS SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2025 AND MARCH 31, 2025 (Amounts in U.S. dollars, except for share and per share data, or otherwis
Charming Medical Limited reported its unaudited interim condensed consolidated financial statements for the period ending September 30, 2025. The company experienced a significant decline in revenues totaling 2,159,935 compared to 2,958,508 in the same period last year. A notable net loss of 72,978 was reported, in stark contrast to the net income of 468,817 in the previous year. Additionally, current liabilities have increased, indicating potential financial challenges for the company as it continues operations.
Read more →-MCTA
Oct 28, 2025▲ +46.9%on this news· ran to +143% by day 3
Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option
Charming Medical Limited announced the full exercise of its representative's over-allotment option, resulting in an additional purchase of 240,000 Class A ordinary shares, boosting total gross proceeds from its initial public offering to approximately US$7.36 million. The Class A shares, priced at $4.00 each, commenced trading on the Nasdaq on October 21, 2025. The company plans to utilize the proceeds for business expansion, strategic investments, research and development, and general working capital. The offering was conducted under a firm commitment basis by Cathay Securities, Inc.
Read more →-MCTA
Oct 22, 2025▼ -11.4%on this news· ran to +38% by day 3
Charming Medical Limited Announces Closing of Initial Public Offering
Charming Medical Limited successfully closed its initial public offering, selling 1,600,000 Class A ordinary shares at $4.00 each, raising $6.4 million. The shares began trading on the Nasdaq Capital Market under the symbol MCTA. The company plans to use the proceeds for business expansion, strategic investments, and research and development.
Read more →-MCTA
Oct 21, 2025Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq
Charming Medical Limited announced the pricing of its initial public offering, offering 1,600,000 Class A ordinary shares at $4.00 each. The company expects to raise about $6.4 million from the IPO, which is set to close on October 22, 2025, contingent upon customary closing conditions. The proceeds will be allocated toward business expansion, strategic investments, research and development, and working capital. The company also has an over-allotment option that could raise total proceeds to approximately $7.36 million.
Read more →About Charming Medical Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next MCTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime